Parvus is pioneering a breakthrough class of disease-specific biological therapeutics called NavacimsTM that are designed to halt and potentially cure autoimmune disease by restoring immune tolerance. The Company’s robust therapeutic platform is capable of generating a rich pipeline of therapeutic candidates for a wide range of autoimmune diseases. Parvus has validated two lead drug candidates to take into clinical development for Type 1 diabetes (T1D) and Multiple Sclerosis (MS), and is scaling up drug product manufacture for GLP toxicology studies.

Parvus operates as a virtual company, maintaining limited office space at the Alastair Ross Technology Center. Their scientific operations are located at the Health Research Innovation Centre, part of the Faculty of Medicine at the University of Calgary.